NCT01721148View on ClinicalTrials.gov

A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Malignant Solid Tumour
Interventions
DRUG

ASLAN002( BMS 777607)

100mg, 200mg, 300mg, 450mg, 600mg

Sponsors
All Listed Sponsors
lead

ASLAN Pharmaceuticals

OTHER

NCT01721148 - A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours | Biotech Hunter | Biotech Hunter